Dr. Budde Highlights Unique Aspects of Mosunetuzumab Trial in Follicular Lymphoma

Video

Elizabeth Lihua Budde, MD, PhD, discusses how the phase I/Ib clinical trial for mosunetuzumab in patients with follicular lymphoma is different than other clinical trials.

Elizabeth Lihua Budde, MD, PhD, an assistant professor at City of Hope, discusses how a phase I/Ib clinical trial evaluating mosunetuzumab in patients with follicular lymphoma (FL) is different than other clinical trials.

Patients receive this novel treatment for a limited number of cycles, Budde says. Initial treatment is only 8 cycles, and the patient may remain in follow-up rather than being treated until progression or relapse.

Recent Videos
Related Content
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN

Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN

Jordyn Sava
January 20th 2025
Article

In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.

Read More

Examining the Non-Hodgkin Lymphoma Treatment Paradigm

Examining the Non-Hodgkin Lymphoma Treatment Paradigm

Nichole Tucker
July 15th 2022
Podcast

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

Listen

Radiotherapy and Abiraterone Improve Outcomes in Low-Volume mCSPC

Radiotherapy and Abiraterone Improve Outcomes in Low-Volume mCSPC

Jordyn Sava
January 17th 2025
Article

In an interview, Cedric Pobel, MD, further discussed the PEACE-1 trial and its findings.

Read More

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

Nichole Tucker
June 15th 2022
Podcast

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

Listen

FDA Approves Axatilimab for Chronic GVHD in New Vial Sizes

FDA Approves Axatilimab for Chronic GVHD in New Vial Sizes

Jordyn Sava
January 16th 2025
Article

Axatilimab has gained FDA approval in 9 mg and 22 mg vials, expanding treatment options for patients with chronic GVHD after 2 prior therapy failures.

Read More

LOTIS-5 Trial of Lonca-R Completes Enrollment in R/R DLBCL

LOTIS-5 Trial of Lonca-R Completes Enrollment in R/R DLBCL

Jordyn Sava
January 14th 2025
Article

Enrollment in the LOTIS-5 trial of loncastuximab tesirine-lpyl with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma has been completed.

Read More